Greetings. Welcome to the Movano 3Q 2021 earnings conference call. At this time, all participants are in a listen only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]. Please note, this conference is being recorded. I will now turn the conference over to your host, J. Cogan, CFO. You may begin.

Thank you operator. Good afternoon everyone. And thank you for joining us today. Our CEO, John Mastrototaro, will open today's call with prepared remarks about the progress we have made during Q3. Afterward, I will cover the highlights of our third quarter 2021 operating results and provide perspective on our financial position. Finally, Movano's Founder and Chief Technology Officer, Michael Leabman, will join John and me for the Q&A session. Before we begin, I would like to remind everyone that we will make forward-looking statements during today's call, whether in prepared remarks or during the Q&A session. These forward-looking statements are subject to inherent risk and uncertainties. These risk and uncertainties are detailed in the risk factors section of our filings with the Securities and Exchange Commission, specifically in the company's IPO prospectus and Forms 10-Q. Except as otherwise required by federal securities laws, Movano disclaims any obligation to update or make revisions to such forward-looking statements contained herein or elsewhere to reflect changes in expectations with regards to those events, conditions and circumstances. Now I would like to turn the call over to our CEO, John Mastrototaro.

Thanks J. And welcome everyone. We appreciate you joining us today for our Q3 earnings call and business update. During the third quarter, we continued to make critical progress on the development of our proprietary technology that will be the foundation of our commercial product pipeline and which aims to empower and inspire individuals to live healthier, happier lives. Since we went public in March, we have been hyper-focused on proving out the technology and building our team. we are following a roadmap that integrates our technology development and plan clinical studies, laying out a path to initial commercial products. We have been determined to make fast progress in these areas, given the significant macro forces at work across health care as the market transitions from a practice of treating the sick to a consumer-driven market focused on preventative care and longevity. Over the past couple of earnings calls, I have referred to this as our crawl, walk, run strategy for product commercialization, which adds functionality and utility in a step-by-step fashion over time to execute our vision safely and thoughtfully. We are taking necessary incremental steps to reach our end goal of bringing a Class II FDA cleared device to the market while at the same time carving a strategic pathway to Class II exempt or Class I product as a way to get our technology in the hands of consumers sooner. Today, our primary goals are as follows. One, to miniaturize our technology to be able to fit in a variety of attractive wearable form factors. Two, to collect as much data as we can to further our algorithm development for blood pressure and glucose monitoring. And three, to develop a best-in-class app and cloud platform to create an exceptional user experience. As we execute against our plan,…

Thanks John. We detailed the financial results in today's 3Q earnings release, which you can find on our website. But let me focus on a few key line items, Movano reported an operating loss of $5.2 million in the third quarter of 2021 compared to an operating loss of $3.2 million in the year ago period. For the nine months ended September 30, 2021, we reported an operating loss of $13.5 million versus $7.9 million in the first nine months of 2020. The increase was primarily related to the expansion of our team and R&D initiatives as well as the inclusion of public company costs related to our March 2021 initial public offering. At the end of the third quarter, we had $39.3 million of cash, cash equivalents and short term investments and total assets of $41.6 million. We will not be providing specific financial guidance but going forward, you should assume we will continue to build our team, increase R&D spending related to a variety of initiatives tied our medical device and testing efforts and continue absorb the cost of being a public company. As we continue to move at a swift pace, make significant progress on the development of our technology and focus our efforts on an initial commercial product, we would expect our burn rate increase in the fourth quarter and into 2022. As that concludes our formal remarks, we would be glad to take your questions. Operator, we are ready to begin the Q&A section of the call.

[Operator Instructions]. J, it looks like we have questions over the webcast. Please go ahead.

They Kyle. Yes. So the first question here, strategies at the CES, who will you be meeting with? John, you want to take that one?

Sure. Look, as you can understand, we are not in a position to name potential meeting participants. But as we have discussed, we believe there are many potential opportunities for partnerships considering the overlap our solution has in the medtech, digital health and consumer space. So our goal is to democratize healthcare and provide solutions to millions of Americans and others around the world. So any partner who could help with the development, distribution and scaling of our efforts is certainly a focus for us and we would certainly be interested in speaking with them.

Great. Let's go to the next question, also on CES. What will you be showing at CES this year?

Well, as you know we have had our heads down working hard to develop simple, smart and personalized devices that will empower and inspire individuals to live happier, healthier lives. Since this is our first CES and we want to showcase the progress we have made, we are going to have exhibits that will show how we have advanced and miniaturized our solution. We have made tremendous progress on the integrated circuit front as well as in the app development and cloud platform. We have also been furthering our algorithm development on blood pressure, glucose and other vital health data through our clinical studies. And we have been strategizing about how to bring a holistic connected digitally-enabled health and wellness solution to the market. There is still plenty work for us to do but we are looking forward to showing and showcasing the great progress that we have made today.

Okay. We have got a few more in the webcast, it looks like. This one says, you have been in stealth mode for a while. What's your plan for communicating going forward?

Thanks for the question. Well, yes, it absolutely true. We have quietly been intensely focused on advancing the technology since the IPO in March. We really committed ourselves to making significant progress and I think as you have seen the development of our wearable prototype, the execution of the clinical studies that we have done, the tape-out of the single-chip solution are all significant major milestones for the company and evidence of the focus that we have had. But we never plan to be in stealth mode forever. As we highlighted in the prepared remarks, we are now at a point where we are going to be a bit more visible and out there highlighting our progress, talking about our vision for the future and ultimately preparing to bring commercial products to the market. We are excited to participate in the Bernstein conference next week, which focuses again on continuous glucose monitoring and disruptive technology in that space. And we are certainly looking forward to our first CES as a company. As we build on the momentum that we have seen in 2021 and enter 2022, I think you can see the pace of progress and likewise the pace of communication to increase over time.

Okay. Great. Next question on the webcast says, when can we expect you to launch a product? This sounds like a 2022 event, perhaps?

Thanks for the question. We are certainly making significant progress with the development of our technology platform. We have been hitting these critical milestones in our path to ultimately launching a commercial product. And we are making necessary investment to prepare the broader organization. But at this point, it's a little too early to put a date out there. But just know that we are very committed to delivering value to both consumers and shareholders. And I would also say that given the macro forces at work in the broader healthcare market with the increasing focus on preventative care and longevity, including the need to help prevent or manage chronic conditions like hypertension and diabetes, there should be plenty of room for us as a company to thrive and we are working as hard as we can to make as much progress as we can as quickly as possible.

Okay. There is one now on cash burn. I can go ahead and take this one. It says, you mentioned in your prepared remarks that your cash burn would increase in the fourth quarter and into next year. By how much? As you are going to see in our upcoming 10-Q, which given the holiday will be published early tomorrow morning, our cash from operations burn was a bit over $11 million for the first nine months of 2021 and a bit more than $3 million for the third quarter, specifically. As we talked about in the past, given our development stage, we are not going to provide specific financial guidance as a general practice. But that said, taking a broad view, the more progress that we are picking on the development of our health technology platform, the more money we will want to invest in additional R&D and other areas of the organization as we begin to prepare for an initial product launch. We have talked about this before, but just to reiterate, we take capital deployment seriously and plan to continue to be very good stewards of the cash on our balance sheet. We are going to try to keep advancing the technology as quickly as possible while at the same time taking a measured approach to incremental investments. And then John, we have a question on blood pressure and glucose, generally asking about focus on one versus the other and where we are at with the algorithm process?

Okay. Yes, sure. Well, look, I think when we first started as an organization, we were looking at glucose as a measurement. And then as we started to make measurements with glucose and we see glucose signals, we also started to see these pulse pressure waveforms in the data that was being collected. And as we looked more closely at that, because were able to see these waveforms, there was the ability and the potential to also look at blood pressure. Our algorithm team really has two focuses. One is to clean up the data that we collect so that we have a signal that we can extract metrics from which will correlate with glucose and blood pressure. And then the other is the algorithm that specifically looks at those analytes of measure. So the first comment I would make is that, any clinical study that we do work for either glucose or blood pressure, the work that we do to improve the sensitivity of our detection of the signals that are coming back to reduce the noise, just improving the quality of the data and the waveform is going to benefit both measures that we make. The second thing that we opted to do recently with our in-house clinical study site is to focus on blood pressure primarily because there is no blood involved. It's an easier study to make because you just wear the blood pressure cuff versus what we are measuring. And so by doing that, we can bring in a lot of people. We can get a wide variety of blood pressures which are beneficial for the algorithm team to look at the deltas. And it's just a little bit more complicated if we want to introduce blood glucose testing to compare with our device and then get a broad range of blood glucose. Obviously both are huge markets, both tremendous opportunities. And at this point, we have elected to collect a lot of data for the blood pressures studies. But what we do there and how we resolve algorithms and whatnot is also applicable to the glucose situation. I think moving forward into 2022, you will see that we continue to run a lot of clinical testing. The last point I will make is that as scale down the size of the technology, as we have gotten to the first wearable prototype, we are seeing that the date is getting cleaner and that also improves our ability to make the measures overall. So a lot of progress in both front and I think there is a lot of continued optimism as we continue to improve the technology and get to a single-chip solution.

Great. Kyle, that looks like all the questions at this time. I don't see any. Do you see any over the phone lines, I am sorry?

There are no questions over the phone. And I will now turn the call over to J. Cogan for closing remarks.

Great. Thanks Kyle. And thanks everybody for your time today. As a reminder, you can stay connected and up-to-date on Movano news and events by checking out our investor website at ir.movano.com.

This concludes today's conference and you may disconnect your lines at this time. Thank you for your participation.